XWP-33992-70919
6 vaccinations
5 coded responses
57 check-ins
4 free-text entries
3 call cases
- Sex
- Male
- Age at first dose
- 66+
- ZIP prefix
- 481 / MI
- Registered
- 2021-02-26
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-26
Registered in v-safe
-
2021-02-26
Dose 1 — Pfizer-BioNTech
- 2021-02-28
- 2021-03-01
- 2021-03-02
- 2021-03-03
- 2021-03-04
- 2021-03-08
- 2021-03-12
-
2021-03-19
Dose 2 — Pfizer-BioNTech
- 2021-03-19
- 2021-03-20
- 2021-03-22
- 2021-03-23
- 2021-03-24
- 2021-03-25
- 2021-03-29
- 2021-04-02
- 2021-04-09
- 2021-04-16
- 2021-04-23
- 2021-04-30
- 2021-06-18
- 2021-09-17
-
2021-09-28
Dose 3 — Pfizer-BioNTech
- 2021-10-03
- 2021-10-04
- 2021-10-05
- 2021-10-12
- 2021-10-19
- 2021-10-26
- 2021-11-02
- 2021-11-09
- 2021-12-30
- 2022-03-29
-
2022-04-07
Dose 4 — Pfizer-BioNTech
- 2022-04-16
- 2022-04-22
- 2022-04-28
- 2022-05-05
- 2022-05-12
-
2022-05-19
Survey response — 42 day, dose 4MedDRA: Dyspnoea exertional, Fatigue, Headache, Laboratory test abnormal, Oropharyngeal pain, Productive cough, Rhinorrhoea, Sleep disorder, Unevaluable event — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationMedDRA releases: 2024-11 · check-in answers available
-
2022-05-19
Report sent to call center — 42 day, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-05-20
Call successfulCompleted over the phone
-
2022-07-07
Survey response — 3 month, dose 4MedDRA: COVID-19, Unevaluable event — Feeling: Good · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationMedDRA releases: 2024-11 · check-in answers available
-
2022-07-07
Report sent to call center — 3 month, dose 4Be unable to do your normal daily activities · Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-07-08
Call successfulReported to VAERS during previous contact from GDIT
-
2022-09-28
Dose 5 — Pfizer-BioNTech
- 2022-09-28
-
2022-09-29
Health check-in — days 1–6 daily, dose 5Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2022-09-30
- 2022-10-01
- 2022-10-02
- 2022-10-04
- 2022-10-05
- 2022-10-12
-
2022-10-19
Survey response — 21 day, dose 5MedDRA: Cough, Fatigue, Pyrexia, SARS-CoV-2 test negative, Secretion discharge, Sneezing, Viral infection — Feeling: Fair · Be unable to do your normal daily activitiesMedDRA releases: 2024-11 · check-in answers available
- 2022-10-26
- 2022-11-02
-
2022-11-09
Survey response — 42 day, dose 5MedDRA: Diarrhoea, Weight decreased — Feeling: FairMedDRA releases: 2024-11 · check-in answers available
- 2022-12-29
-
2023-03-29
Survey response — 6 month, dose 5MedDRA: Weight decreased — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11 · check-in answers available
-
2023-03-29
Report sent to call center — 6 month, dose 5Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2023-03-30
-
2023-04-27
Dose 6 — Pfizer-BioNTech
- 2023-05-11
- 2023-05-18
- 2023-05-25
- 2023-06-01
- 2023-06-08
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-26 | Pfizer-BioNTech | |
| 2 | 2021-03-19 | Pfizer-BioNTech | |
| 3 | 2021-09-28 | Pfizer-BioNTech | No |
| 4 | 2022-04-07 | Pfizer-BioNTech | No |
| 5 | 2022-09-28 | Pfizer-BioNTech | No |
| 6 | 2023-04-27 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-05-19 | Successful 2022-05-20 |
Completed over the phone |
| 2022-07-07 | Successful 2022-07-08 |
Reported to VAERS during previous contact from GDIT |
| 2023-03-29 | Unsuccessful |
Free text
Release 11
Symptoms: Tested positive on 2-18-22 and symptoms started on 2-16---moderate fatigue, productive cough, headache, sore throat, running nose, dyspnea on any exertion, somewhat worse sleep
Healthcare visit (other): My PCP started paxlovid
Release 12
Symptoms: A mild case of covid-19.
Healthcare visit (other): Took paxlovid for 5 days
Symptoms: Virus symptoms with a lot of mucus sneezing, fatigue and some cough But I tested negative for antigen covid test and symptoms are diminishing now. Had a mild fever for today's. Symptoms started on October 15th and are trailing off today October 19. cut off by CDC
Symptoms: Loose bowels and 3 pound weight loss
Free-text releases are not linked to a specific survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Unevaluable event | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Diarrhoea | · | · | ✓ |
| SD | Dyspnoea exertional | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Laboratory test abnormal | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Productive cough | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
| SD | Secretion discharge | · | · | ✓ |
| SD | Sleep disorder | · | · | ✓ |
| SD | Sneezing | · | · | ✓ |
| SD | Viral infection | · | · | ✓ |
| SD | Weight decreased | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release